David Malcom Rodman Sells 11,367 Shares of Mineralys Therapeutics (NASDAQ:MLYS) Stock

Key Points

• Mineralys Therapeutics insider David Malcom Rodman sold 11,367 shares of stock for approximately $409,212, decreasing his ownership by 12.24%, leaving him with 81,524 shares valued at nearly $2.93 million.
• The company's stock has shown significant growth, trading up 3.3% recently, with a current price of $37.42 and a 52-week high of $39.20.
• Mineralys Therapeutics recently reported earnings of ($0.66) per share, surpassing the consensus estimate by $0.12, with analysts forecasting a modest EPS of -4.23 for the current fiscal year.

Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Get Free Report) insider David Malcom Rodman sold 11,367 shares of the firm's stock in a transaction that occurred on Monday, September 15th. The stock was sold at an average price of $36.00, for a total transaction of $409,212.00. Following the transaction, the insider directly owned 81,524 shares of the company's stock, valued at $2,934,864. This represents a 12.24% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

David Malcom Rodman also recently made the following trade(s):

• On Wednesday, August 13th, David Malcom Rodman sold 11,365 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $12.93, for a total transaction of $146,949.45.
• On Monday, July 14th, David Malcom Rodman sold 11,366 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $14.59, for a total transaction of $165,829.94.

Mineralys Therapeutics Stock Down 2.4%

Shares of NASDAQ:MLYS traded down $0.98 during trading on Friday, hitting $38.90. 645,724 shares of the stock traded hands, compared to its average volume of 1,088,529. The company has a market cap of $2.58 billion, a price-to-earnings ratio of -10.95 and a beta of -0.29. The company has a fifty day moving average price of $19.81 and a two-hundred day moving average price of $16.25. Mineralys Therapeutics, Inc. has a 52-week low of $8.24 and a 52-week high of $40.33.

Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last posted its earnings results on Tuesday, August 12th. The company reported ($0.66) earnings per share for the quarter, beating the consensus estimate of ($0.78) by $0.12. On average, equities research analysts predict that Mineralys Therapeutics, Inc. will post -4.23 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. SBI Securities Co. Ltd. raised its stake in Mineralys Therapeutics by 297.5% in the 1st quarter. SBI Securities Co. Ltd. now owns 1,590 shares of the company's stock valued at $25,000 after purchasing an additional 1,190 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in Mineralys Therapeutics by 51.0% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,518 shares of the company's stock valued at $34,000 after purchasing an additional 850 shares during the last quarter. BNP Paribas Financial Markets acquired a new position in Mineralys Therapeutics in the 4th quarter valued at about $48,000. Ameritas Investment Partners Inc. raised its stake in Mineralys Therapeutics by 42.8% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,995 shares of the company's stock valued at $54,000 after purchasing an additional 1,197 shares during the last quarter. Finally, KLP Kapitalforvaltning AS acquired a new position in Mineralys Therapeutics in the 2nd quarter valued at about $91,000. Institutional investors and hedge funds own 84.46% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on MLYS shares. Wall Street Zen raised Mineralys Therapeutics from a "sell" rating to a "hold" rating in a research note on Friday, August 22nd. The Goldman Sachs Group upped their price objective on shares of Mineralys Therapeutics from $32.00 to $52.00 and gave the company a "buy" rating in a report on Tuesday, September 9th. HC Wainwright reaffirmed a "buy" rating and issued a $42.00 target price on shares of Mineralys Therapeutics in a research report on Monday, September 8th. Jefferies Financial Group increased their price target on shares of Mineralys Therapeutics from $15.00 to $26.00 and gave the stock a "hold" rating in a research report on Wednesday, September 3rd. Finally, Bank of America raised their target price on shares of Mineralys Therapeutics from $38.00 to $43.00 and gave the company a "buy" rating in a report on Thursday, August 28th. Five research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $43.50.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.